LimmaTech Biologics Receives $37 Million Investment

Zurich-based LimmaTech Biologics AG, a clinical-stage biopharmaceutical company, announced that it has secured $37 million (approximately EUR 35 million) in a Series A financing round. It was co-led by Adjuvant Capital, AXA IM Alts and Novo Holdings REPAIR Impact Fund. With this agreement, Kabeer Aziz from Adjuvant Capital, PhD Zina Affas Besse from AXA IM Alts and PhD Camilla Petrycer Hansen from Novo Holdings will take part. She will join LimmaTech's Board of Directors.

Also See: Audoo Receives $5 Million Investment

LimmaTech Biologics

What do we know about Antimicrobial Resistance (AMR)? AMR is a serious global health crisis that causes nearly 5 million deaths annually. Almost one million of these deaths are children under the age of five. These numbers are also increasing rapidly. Historically, antibiotics have effectively treated bacterial infections. However, their inappropriate and excessive use has led bacteria to develop natural resistance. As a result, infections that were once easily treatable have become almost impossible to cure.

For example, half of the 700,000 annual gonorrhoea infections in the USA are already antibiotic resistant. It poses a significant threat. Note for similar concerns. It also applies to infections such as Shigella, which causes 450,000 infections in the US and 700,000 deaths worldwide each year, particularly affecting children. Given the slow pace of discovery of new antibiotics compared to the rapid growth of AMR, the development of vaccines targeting multidrug-resistant pathogens is vital in combating this deadly global health threat.

Founded in 2015 and a spin-off of GlycoVaxyn following its acquisition by GSK, LimmaTech Biologics specialises in developing advanced vaccines to combat life-threatening diseases. Focusing on the growing global threat of infection due to emerging antimicrobial resistance, including diseases such as gonorrhoea, LimmaTech is developing its proprietary clinical pipeline. Note for LimmaTech Biologics. It is committed to translating scientific concepts into highly effective vaccines aimed at benefiting humanity.